BioVie
BioVie is a purpose-based company.
Through innovation, collaboration, and people centered science, BioVie is creating new solutions enabling people to live healthier and better lives.
Alzheimers:
BioVie believes that inflammation is central to the development and progression of Alzheimer’s Disease. BioVie’s different approach focuses on our novel molecule, NE3107, currently being studied in people diagnosed with Alzheimer’s Disease, and the hypotheses that selective modulation of inflammation, and the enhancement of energy transfer (insulin sensitivity) in the brain, may be able to improve memory and thinking, and may protect against neurodegeneration. Perhaps, if our studies are successful, NE3107 may be able to provide future benefit to the millions of people diagnosed with Alzheimer’s, as well as to the families, friends, and professionals who care for them.
Parkinsons:
BioVie is committed to developing therapies to help people suffering from Parkinson’s. BioVie is now testing NE3017 in human clinical studies in Parkinson’s Disease based on promising results from their preclinical trials.
Ascites / Cirrhosis Research:
BioVie is especially focused on exploring the treatment of ascites (the excessive accumulation of fluid in the abdomen). Ascites often occurs in the presence of advanced liver cirrhosis, which can be caused by the progression of NASH (non-alcoholic steatohepatitis), infection with Hepatitis B & C, alcoholism, and other causes. Ascites is, indeed, the most common complication of advanced (“decompensated”) liver cirrhosis. Complications of ascites can be life-threatening.
